Trial
NCT01573247
Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Akinion Pharmaceuticals AB
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
AKN-028
Why stopped
During the study two patients have experienced serious liver events related to AKN-028. The risk-benefit balance was judged to be negative.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-25